The ODYSSEY-HCM trial found that mavacamten did not significantly improve exercise capacity or patient-reported outcomes in individuals with symptomatic nonobstructive hypertrophic cardiomyopathy. Safety concerns emerged, including more frequent reductions in ejection fraction and treatment interruptions among those receiving mavacamten. The trial's limited diversity and short duration raise questions about the generalizability and long-term implications of the findings. Despite the lack of approved therapies for this patient group, the study underscores the complexity of using surrogate endpoints and the need for deeper exploration into disease mechanisms and treatment response.

In this interview, Matthew Martinez MD, FACC and Milind Y. Desai, MD, MBA, FACC discuss "ODYSSEY-HCM: Mavacamten in nHCM."

Subscribe on Apple Podcasts | Subscribe to ACCEL